Free Webinar · July 17 12pm PT · Reserve your spot →
OCD is considered treatment-resistant when there’s been an inadequate response to at least two adequate trials of SSRIs (often at higher than usual doses) plus structured ERP therapy. An estimated 40-60% of OCD patients meet this criterion at some point [1]. The standard escalation is augmentation with atypical antipsychotics, clomipramine, glutamate-modulating medications, or in severe cases TMS or DBS. Functional medicine adds a parallel investigation — looking for what biological signal is sustaining the OCD circuitry.
OCD has historically been framed as a serotonin condition, but the mechanistic picture is broader. Glutamate hyperactivity in the cortico-striato-thalamo-cortical circuit is now understood to be central. Neuroinflammation, autoimmune activity, and chronic infection drivers can all sustain that circuit’s dysregulation in ways an SSRI won’t reach.
The presence of OCD doesn’t mean the biology is the cause. But in treatment-resistant cases, the biology is worth investigating.
The mechanisms most consistently implicated in chronic, treatment-resistant OCD:
Originally identified in pediatric OCD following streptococcal infection, the broader category — Pediatric Acute-onset Neuropsychiatric Syndrome — applies to adults too. Autoantibodies cross-react with basal ganglia neurons, sustaining OCD symptoms via immune activity rather than primary neurochemistry [2].
Borrelia, Bartonella, mycoplasma, Epstein-Barr Virus (EBV) reactivation, and other persistent infections have been linked to OCD-spectrum presentations.
N-acetylcysteine (NAC) at therapeutic doses has shown benefit in OCD, working through glutamate modulation and antioxidant pathways [3].
Both undermethylation and overmethylation patterns have been described in subsets of OCD; they call for very different supplement strategies.
Intestinal permeability and microbiome shifts can amplify systemic inflammation that reaches the central nervous system (CNS).
A subset of patients show clear symptom escalation in mold-exposed environments and improvement with environmental remediation.
Myo-inositol at high doses has shown benefit in OCD, working on second-messenger signaling.
Premenstrual Dysphoric Disorder (PMDD)-pattern symptom escalation, perimenopausal worsening, and post-pregnancy onset all point to estrogen-progesterone interactions with the OCD circuit.
For OCD, the immune and inflammatory markers in our blood panel matter especially — hs-CRP, ANA, and where indicated additional autoimmune workup. The GI Effects stool panel reveals dysbiosis and inflammation. KBMO FIT 176 with Gut Barrier Panel maps food sensitivities and intestinal permeability that may contribute to neuroinflammation. NutrEval shows whether glutathione, NAC precursors, and methylation cofactors are depleted. 3×4 Genetics shows methylation, GAD, and immune-pathway variants.
For some patients we recommend additional testing beyond our core bundle — Cyrex Array for tissue-specific autoimmunity, mycotoxin panels, or chronic infection workups. These get added based on what your initial picture suggests.
If you’ve already had autoimmune or infectious workup elsewhere, send it.
When immune or inflammatory drivers are identified, phase one usually addresses gut barrier integrity, systemic inflammation, and nutrient cofactors that support the methylation and glutathione systems. NAC, where appropriate, is one of the better-studied OCD-relevant interventions. Where infection or autoimmunity is significant, longer-term protocols are coordinated across the team and with your psychiatric prescriber. SSRIs and ERP are not stopped — they’re potentiated by addressing what’s been driving the resistance.
Program structure: main services page
This work fits people whose OCD has resisted conventional treatment, who are open to investigating possible inflammatory or immune contributors, and who can commit to structured, multi-phase work. We coordinate closely with prescribers and ERP therapists — this is parallel work, not competing work.